Breast Cancer

Experiments were conducted on the private datasets (HER2USC) and the public datasets (BCW, BCa and SIIM-ISIC). Experimental results demonstrate that KMNet outperformed other reported state-ofthe- art multi-modal algorithms in HER2 subtyping task, offering strong potential for clinical decision support in breast cancer treatment.

MRI radiomic subregional analysis captures spatial heterogeneity linked to NAC response. GATA3 serves as a radiogenomic biomarker linking imaging phenotypes to transcriptomic programs. Integrating imaging, genomic, and environmental data may refine personalized response prediction.

These findings suggest that addition of an Akt inhibitor to RT and ICBs leads to a less immunosuppressive tumor microenvironment by modulating myeloid cells. Taken together, Akt inhibition could be a viable strategy to overcome therapeutic resistance of ICBs and RT in breast cancer.

These data add to the current view that nanobody selection for CAR design remains subject to extensive side-by-side screening. Still, superior cytotoxicity across multiple solid tumor cell lines-determined using in vitro assays evaluating activation, cytokine secretion, and target cell-specific killing-led to selection and further characterization of a lead nanoCAR 1R59b, showing tumor control in an in vivo xenograft model, providing a promising HER2 nanoCAR for further (pre)clinical investigation.

This study classified BC by mRNAsi-related genes and established corresponding risk models. The findings of the present study propose a novel classification tool based on stem cell characteristics, which has the potential to be employed for prognostic stratification in BC patients and to offer guidance for developing personalised treatment strategies.

They were treated with savolitinib as the second-line treatment after previously receiving AP regimens (pemetrexed + cisplatin). The case series demonstrated that savolitinib has a favorable clinical efficacy and safety profile, suggesting its potential as a key therapeutic option for elderly patients with NSCLC harboring METex14 skipping mutations. The treatment offers sustained survival benefits and is well-tolerated.

Pyrotinib showed good antitumor activity in the treatment of patients with HER2-positive advanced breast cancer and displayed a degree of efficacy in patients with brain metastases. The main adverse reaction was diarrhea, which was mostly low to moderate in severity, and the incidence of high-grade AEs was generally low, with controllable toxicity.

Transcriptomic profiling of tumors developed in Mgl2 -deficient mice revealed a shift toward an inflammatory, immune-activated state consistent with enhanced antitumor immunity. Together, these findings establish a link between tumor glycosylation and lectin signaling of myeloid cells, highlighting CD301b as a potential target for reprogramming the tumor immune microenvironment in breast cancer.

Conversely, patients within the high-risk category are more likely to benefit from NAC and should be prioritized for this treatment to maximize survival gains. Prospective integration of targeted therapy data will refine these precision oncology tools.

Survival sequential analysis highlights subtype-specific surveillance priorities: intensified monitoring within 3 years for TNBC, focused follow-up at 7-8 years for HER2-positive subtype, and extended tracking for Luminal subtypes. Both nomograms and the RSF model demonstrated robust predictive performance, providing theoretical and practical tools for precision prognosis management in breast cancer.

Adjuvant RT did not improve the OS and BCSS of the M0 ADCC patients with tumors ≤10 mm who had undergone BCT. Therefore, adjuvant RT may not be necessary for M0 ADCC patients with tumors ≤10 mm who have undergone BCT.

Collectively, the present study establishes the potential of Houttuynia cordata-derived exosome-like nanovesicles as a natural therapeutic platform against TNBC, with macrophage membrane coating further augmenting their efficacy through biomimetic targeting. MCELNs may represent a promising drug delivery strategy for enhancing treatment efficacy while minimizing systemic toxicity in breast cancer therapy.